Transpact Enterprises P/E Ratio
Transpact Enterprises (TRANSPACT) P/E ratio is 869.57 (High), EPS (TTM) ₹0.23, current price ₹ on None — Very High - High growth expectations or significantly overvalued. For live price, revenue and the complete fundamental profile, see TRANSPACT stock overview.
Current P/E Ratio
869.57
High Valuation
Very High - High growth expectations or significantly overvalued
Current Valuation Metrics
P/E Ratio
869.57
Current Price
₹
EPS (TTM)
₹0.23
Exchange
None
Valuation Signal
Signal
Overvalued
Sector Context
Sector Average
43.05
Sector Median
26.94
Sector Rank
#11 of 139
Sector Percentile
7.9%
TRANSPACT P/E Ratio — Valuation Signal & Historical Context
Transpact Enterprises P/E 869.57 — signal: Overvalued. Analyse TRANSPACT shareholder distribution to track promoter, FII and institutional holdings.
- Stock appears overvalued with PE of 869.57, suggesting caution for new investments
- Trading at premium to sector average PE of 43.05
TRANSPACT vs Healthcare Peers — P/E Ratio Comparison
Transpact Enterprises P/E 869.57 vs Healthcare average 43.05, median 26.94 — range 1.17–783.37.
Sector Average
43.05
Sector Median
26.94
Lowest P/E
1.17
Highest P/E
783.37
Companies
139
| Company | Symbol | P/E Ratio | Market Cap (₹ Cr) | Valuation |
|---|---|---|---|---|
| Welcure Drugs & Pharmace… | WELCURE | 1.17 | ₹43 | Low |
| Murae Organisor | MURAE | 2.86 | ₹41 | Low |
| Ind Swift Laboratories | INDSWFTLAB | 4.93 | ₹1,136 | Low |
| Amwill Health Care | AMWILL | 5.67 | ₹64 | Low |
| Medicamen Organics | MEDIORG | 6.4 | ₹27 | Low |
| Zenith Drugs | ZENITHDRUG | 6.83 | ₹69 | Low |
| Unichem Laboratories | UNICHEMLAB | 7.99 | ₹2,364 | Low |
| Galaxy Medicare | GML | 8.78 | ₹31 | Low |
| Brooks Laboratories | BROOKS | 9.86 | ₹211 | Low |
| Accretion Pharmaceuticals | ACCPL | 10.92 | ₹78 | Low |